• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.

作者信息

Nierengarten Mary Beth

出版信息

Cancer. 2023 Aug 1;129(15):2278. doi: 10.1002/cncr.34910.

DOI:10.1002/cncr.34910
PMID:37401895
Abstract
摘要

相似文献

1
Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.
Cancer. 2023 Aug 1;129(15):2278. doi: 10.1002/cncr.34910.
2
Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer.
J Clin Oncol. 2022 Dec 20;40(36):4278-4279. doi: 10.1200/JCO.22.01084. Epub 2022 Aug 19.
3
Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?恩杂鲁胺与醋酸亮丙瑞林治疗非转移性激素敏感性前列腺癌：越早越好？
Future Oncol. 2024 Feb;20(4):163-166. doi: 10.2217/fon-2023-1019. Epub 2024 Feb 7.
4
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.恩杂鲁胺治疗去势抵抗性前列腺癌非转移患者。
Expert Opin Pharmacother. 2020 Dec;21(17):2091-2099. doi: 10.1080/14656566.2020.1803281. Epub 2020 Aug 12.
5
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.恩杂鲁胺用于在化疗前治疗转移性激素复发前列腺癌：© 英国国家卫生与临床优化研究所（2016年）恩杂鲁胺用于在化疗前治疗转移性激素复发前列腺癌。
BJU Int. 2017 Aug;120(2):168-184. doi: 10.1111/bju.13936.
6
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.在TERRAIN试验中恩杂鲁胺与比卡鲁胺治疗年轻和老年转移性去势抵抗性前列腺癌患者的疗效与安全性
J Urol. 2018 Jan;199(1):147-154. doi: 10.1016/j.juro.2017.08.080. Epub 2017 Aug 19.
7
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.恩扎卢胺在日本根治性治疗后复发的联合雄激素阻断治疗的非转移性去势抵抗性前列腺癌患者中的应用（日本非转移性去势抵抗性前列腺癌患者的研究-恩扎卢胺：JCASTRE-zero）-一项前瞻性单臂干预性研究。
BMC Urol. 2022 Sep 14;22(1):151. doi: 10.1186/s12894-022-01096-3.
8
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.一项关于转移性去势抵抗性前列腺癌患者恩扎卢胺的欧洲、前瞻性、观察性研究：PREMISE。
Int J Cancer. 2022 Mar 1;150(5):837-846. doi: 10.1002/ijc.33845. Epub 2021 Nov 8.
9
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.转移性去势敏感性前列腺癌中依泽替米贝联合雄激素剥夺治疗的疗效：ARCHES 事后分析。
J Urol. 2021 May;205(5):1361-1371. doi: 10.1097/JU.0000000000001568. Epub 2020 Dec 28.
10
Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.关于：多西他赛治疗转移性去势抵抗性前列腺癌进展后持续使用恩杂鲁胺（PRESIDE）：一项国际随机3b期研究。
Eur Urol. 2023 Jul;84(1):141-142. doi: 10.1016/j.eururo.2023.02.021. Epub 2023 Mar 2.